Receptos to Deliver Scientific Presentations About RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
10/2/2013 9:48:54 AM
SAN DIEGO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel will deliver two scientific poster presentations about RPC1063 at the annual meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark during October 2-5, 2013. RPC1063 is the Company's lead sphingosine 1-phosphate 1 receptor (S1P1R) modulator in Phase 2 development for both relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD).
Help employers find you! Check out all the jobs and post your resume.